Sign in Register

Drug class

Antithrombin Agents

Antithrombin agents encompass therapeutic formulations of antithrombin—a naturally occurring plasma glycoprotein and serine protease inhibitor—as well as direct antithrombin or thrombin-inhibiting therapies. Read more about Antithrombin Agents

164 drugs in this class 74 manufacturers

Related classes & indications

Calcium Channel BlockersCardiovascular & renal · 344 prescription drugs Angiotensin II Receptor Antagonists (ARBs)Cardiovascular & renal · 281 prescription drugs Acute Myocardial InfarctionTop indication · 141 prescription drugs

Showing 64–72 of 164 drugs

Sort

HEPARIN SODIUM-0.45% NACL (heparin sodium,porcine in 0.45 % sodium chloride)

HEPARIN · DISSEMINATED INTRAVASCULAR COAGULATION ·+7

FRESENIUS KABI

ENOXAPARIN (enoxaparin sodium)

HEPARIN · DEEP VENOUS THROMBOSIS ·+8

Amphastar Pharmaceuticals

HEPARIN (PORCINE) (heparin sodium,porcine)

HEPARIN · DISSEMINATED INTRAVASCULAR COAGULATION ·+7

MEITHEAL PHARMA

HEPARIN (PORCINE) (heparin sodium,porcine)

HEPARIN · DISSEMINATED INTRAVASCULAR COAGULATION ·+7

CIVICA, INC.

ENOXAPARIN (enoxaparin sodium)

HEPARIN · DEEP VENOUS THROMBOSIS ·+8

FRESENIUS KABI

HEPARIN, PORCINE (PF) (heparin sodium,porcine/PF)

HEPARIN · DISSEMINATED INTRAVASCULAR COAGULATION ·+7

MEITHEAL PHARMA

HEPARIN (PORCINE) IN 0.9% NACL (heparin sodium,porcine in 0.9 % sodium chloride)

HEPARIN

QUVA PHARMA, IN

HEPARIN, PORCINE (PF) (heparin sodium,porcine/PF)

HEPARIN · DISSEMINATED INTRAVASCULAR COAGULATION ·+7

FRESENIUS KABI

ELIQUIS DVT-PE TREAT 30D START (apixaban)

ORAL ANTICOAGULANTS · PULMONARY THROMBOEMBOLISM ·+5

BMS PRIMARYCARE

Filter & compare in the drug finder → Opens the drug finder with Antithrombin Agents preselected. Add indication or manufacturer filters there.

About Antithrombin Agents.

Antithrombin agents encompass therapeutic formulations of antithrombin—a naturally occurring plasma glycoprotein and serine protease inhibitor—as well as direct antithrombin or thrombin-inhibiting therapies.

In therapeutic replacement, these agents function by binding to and inactivating thrombin and other activated clotting factors (such as factor Xa), a process markedly accelerated by heparin, thereby dampening the coagulation cascade and preventing thrombus formation.

In clinical pharmacology, they are primarily indicated for the treatment and prophylaxis of thromboembolism—particularly peri-operative and peri-partum venous thromboembolic events—in patients with hereditary antithrombin deficiency, and broadly serve as antithrombotic therapies across specialized thromboembolic disorders.

fda.gov
Antithrombin agents encompass therapeutic formulations of antithrombin—a naturally occurring plasma glycoprotein and serine protease inhibitor—as well as direct antithrombin or thrombin-inhibiting therapies In clinical pharmacology, they are primarily indicated for the treatment and prophylaxis of thromboembolism—particularly peri-operative and peri-partum venous thromboembolic events—in patients with hereditary antithrombin deficiency, and broadly serve as antithrombotic therapies across specia...
nih.gov
Antithrombin agents encompass therapeutic formulations of antithrombin—a naturally occurring plasma glycoprotein and serine protease inhibitor—as well as direct antithrombin or thrombin-inhibiting therapies In clinical pharmacology, they are primarily indicated for the treatment and prophylaxis of thromboembolism—particularly peri-operative and peri-partum venous thromboembolic events—in patients with hereditary antithrombin deficiency, and broadly serve as antithrombotic therapies across specia...
nih.gov
Antithrombin agents encompass therapeutic formulations of antithrombin—a naturally occurring plasma glycoprotein and serine protease inhibitor—as well as direct antithrombin or thrombin-inhibiting therapies In therapeutic replacement, these agents function by binding to and inactivating thrombin and other activated clotting factors (such as factor Xa), a process markedly accelerated by heparin, thereby dampening the coagulation cascade and preventing thrombus formation
fda.gov
In therapeutic replacement, these agents function by binding to and inactivating thrombin and other activated clotting factors (such as factor Xa), a process markedly accelerated by heparin, thereby dampening the coagulation cascade and preventing thrombus formation
drugbank.com
In therapeutic replacement, these agents function by binding to and inactivating thrombin and other activated clotting factors (such as factor Xa), a process markedly accelerated by heparin, thereby dampening the coagulation cascade and preventing thrombus formation
fda.gov
In clinical pharmacology, they are primarily indicated for the treatment and prophylaxis of thromboembolism—particularly peri-operative and peri-partum venous thromboembolic events—in patients with hereditary antithrombin deficiency, and broadly serve as antithrombotic therapies across specialized thromboembolic disorders